{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/reducing-white-space-early-stage-drug-development-strategies-streamlined-success#webpage",
"url": "https://www.fortrea.com/insights/reducing-white-space-early-stage-drug-development-strategies-streamlined-success",
"name": "Reducing white space in early-stage drug development: Strategies for streamlined success",
"description": "Explore this Fortrea white paper on reducing white space in drug development and discover how integrated development strategies are helping organizations improve efficiency, reduce delays, and streamline clinical development processes across the product lifecycle. The white paper examines the impact of operational gaps and inefficiencies in drug development while highlighting approaches to clinical development optimization, cross-functional planning, coordinated execution, faster decision-making, and streamlined development workflows. Learn how integrated drug development strategies, collaborative planning models, proactive milestone management, development lifecycle coordination, and process optimization approaches are helping organizations reduce operational bottlenecks, accelerate development timelines, improve clinical trial efficiency, and support more connected and efficient drug development programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Reducing white space in early-stage drug development: Strategies for streamlined success",
"item": "https://www.fortrea.com/insights/reducing-white-space-early-stage-drug-development-strategies-streamlined-success"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/recognizing-new-normal-patient-centric-clinical-studies#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/recognizing-new-normal-patient-centric-clinical-studies#webpage"
},
"headline": "Reducing White Space in Drug Development Through Integrated Development Strategies | Fortrea White Paper",
"description": "Explore this Fortrea white paper on reducing white space in drug development and discover how integrated development strategies are helping organizations improve efficiency, reduce delays, and streamline clinical development processes across the product lifecycle. The white paper examines the impact of operational gaps and inefficiencies in drug development while highlighting approaches to clinical development optimization, cross-functional planning, coordinated execution, faster decision-making, and streamlined development workflows. Learn how integrated drug development strategies, collaborative planning models, proactive milestone management, development lifecycle coordination, and process optimization approaches are helping organizations reduce operational bottlenecks, accelerate development timelines, improve clinical trial efficiency, and support more connected and efficient drug development programs.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-11-21",
"dateModified": "2025-11-21",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-02/recognizing-new-normal-of-patient-centric-clinical-studies.pdf",
"encodingFormat": "application/pdf"
}
}
]
}